Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Sep:182:4-13.
doi: 10.1016/j.clim.2017.04.003. Epub 2017 Apr 8.

Innate immunity in Sjögren's syndrome

Affiliations
Review

Innate immunity in Sjögren's syndrome

Jeremy Kiripolsky et al. Clin Immunol. 2017 Sep.

Abstract

Sjögren's syndrome (SS) is an autoimmune disease of exocrine tissue that primarily affects women. Although patients typically experience xerostomia and xerophthalmia, numerous systemic disease manifestations are seen. Innate immune hyperactivity is integral to many autoimmune diseases, including SS. Results from SS mouse models suggest that innate immune dysregulation drives disease and this is a seminal event in SS pathogenesis. Findings in SS patients corroborate those in mouse models, as innate immune cells and pathways are dysregulated both in exocrine tissue and in peripheral blood. We will review the role of the innate immune system in SS pathogenesis. We will discuss the etiology of SS with an emphasis on innate immune dysfunction. Moreover, we will review the innate cells that mediate inflammation in SS, the pathways implicated in disease, and the potential mechanisms governing their dysregulation. Finally, we will discuss emerging therapeutic approaches to target dysregulated innate immune signaling in SS.

Keywords: A253; Innate immunity; Sjögren's syndrome; Submandibular gland; Toll-like receptor.

PubMed Disclaimer

Figures

Figure 1
Figure 1. LPS activates TLR4 signaling in A253 cells
A253 cells were purchased from American Type Culture Collection. Cells were cultured in McCoy’s 5A (Modified) Media containing 10% heat-inactivated FBS, 2 mM L-glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin in 6 well plates. (A) A253 cells (3.5 × 105) were harvested, and relative TLR4, Ly96, CD14, and MyD88 transcript levels were quantified by real time PCR. Each sample was analyzed in duplicate and normalized expression relative to GAPDH is shown. (B) A253 cells were harvested and cultured in the presence or absence of LPS (10 µg/mL) derived from Salmonella typhimurium for 24 h. Tissue was fluorescently stained with isotype control (grey shading) or TLR4 antibody. The red line represents unstimulated cells and the blue line indicates LPS treated cells. (C) A253 cells (3.0 × 105) were incubated in the presence or absence LPS (10 µg/mL) for 24 h. Cells were lysed and western blots performed for MyD88. All samples were normalized to GAPDH. (D) A253 cells (3.0 × 105) were stimulated with LPS (10 µg/mL) for the indicated times. Phosphorylated p65 was normalized to total p65 levels. Results of at least three independent experiments are shown (min = minutes).
Figure 2
Figure 2. LPS induces inflammatory cytokine secretion in A253 cells
A253 cells (3.0 × 105) were cultured in the presence or absence of LPS (10 µg/mL) for 24 h, and the supernatant harvested. (A) IL-6, (B) IL-12, (C) MCP-1, (D) RANTES, and (E) GM-CSF were assessed by multiplex array. All samples were analyzed in triplicate and results of three independent experiments are shown (* p < 0.05, ** p < 0.001, *** p < 0.0001, N.S. = non significant).

Similar articles

Cited by

References

    1. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, Liang MH, Kremers HM, Mayes MD, Merkel PA, Pillemer SR, Reveille JD, Stone JH, N.A.D. Workgroup Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58:15–25. - PubMed
    1. Malladi AS, Sack KE, Shiboski SC, Shiboski CH, Baer AN, Banushree R, Dong Y, Helin P, Kirkham BW, Li M, Sugai S, Umehara H, Vivino FB, Vollenweider CF, Zhang W, Zhao Y, Greenspan JS, Daniels TE, Criswell LA. Primary Sjogren's syndrome as a systemic disease: a study of participants enrolled in an international Sjogren's syndrome registry. Arthritis care & research. 2012;64:911–918. - PMC - PubMed
    1. Kramer JM. Current concepts in Sjogren's syndrome and considerations for the dental practitioner. The New York state dental journal. 2015;81:24–29. - PubMed
    1. Hansen A, Lipsky PE, Dörner T. B cells in Sjögren's syndrome: indications for disturbed selection and differentiation in ectopic lymphoid tissue. Arthritis Res Ther. 2007;9:218. - PMC - PubMed
    1. Ambrosi A, Wahren-Herlenius M. Update on the immunobiology of Sjogren's syndrome. Curr Opin Rheumatol. 2015;27:468–475. - PubMed

Publication types